Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs provides a whole spectrum of premium anti-IL2RA recombinant antibodies. These antibodies are designed for optimal performance. Applying our superior technology guarantees incredible specificity, stability, and effectiveness in these antibodies, thereby making them essential tools for researchers and developers focused on targeted cancer medicines.
The interleukin-2 receptor alpha chain (CD25) functions as a critical component required for the assembly of high-affinity interleukin-2 receptors. Elevated expression of this receptor subunit, particularly its soluble isoform (sCD25), demonstrates strong correlations with both autoimmune disorders and malignant conditions. This soluble variant is generated during immune activation and has become an important biomarker for tracking disease trajectories and therapeutic responses. The molecule shows particular relevance in pathological immune hyperactivation scenarios, including cytokine release syndromes that may progress to multi-organ dysfunction. These biological properties position CD25/IL-2RA as a compelling molecular target for innovative cancer therapies.
Interleukin 2 receptor subunit alpha; CD25; interleukin-2 receptor alpha chain; Tac antigen; P55; IDDM10; IL2R; TCGFR; IMD41.
The interleukin 2 (IL2) receptor alpha (IL2RA) and beta (IL2RB) chains, together with the common gamma chain (IL2RG), constitute the high-affinity IL2 receptor. Homodimeric alpha chains (IL2RA) result in low-affinity receptor, while homodimeric beta (IL2RB) chains produce a medium-affinity receptor. Normally an integral-membrane protein, soluble IL2RA has been isolated and determined to result from extracellular proteolysis. Alternately-spliced IL2RA mRNAs have been isolated, but the significance of each is presently unknown. Mutations in this gene are associated with interleukin 2 receptor alpha deficiency.
With a great range of recombinant anti-IL2RA antibodies, each meticulously crafted for extraordinary specificity and affinity, Creative Biolabs offers varied forms of our antibodies, allowing us to satisfy varied study needs. These antibodies, which use our sophisticated platform, are modern instruments to further immunology, cancer biology, and allied fields of study as well as help to produce next-generation medicines.
Table 1. Featured anti-IL2RA recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
AFC-TAB-023 | Afuco™ Anti-IL2RA ADCC Recombinant Antibody (Daclizumab), ADCC Enhanced | Human | Human ADCC enhanced antibody | ELISA, Neut, IF, IP, FC, FuncS |
AFC-TAB-004 | Afuco™ Anti-IL2RA ADCC Recombinant Antibody (Basiliximab), ADCC Enhanced | Human | Chimeric (mouse/human) ADCC enhanced antibody | IF, IP, Neut, FuncS, ELISA, FC |
TAB-023 | Anti-Human CD25 Recombinant Antibody (Daclizumab) | Human | Mouse IgG1 - kappa | ELISA, Neut, IF, IP, FC, FuncS, MRI |
TAB-004 | Anti-Human CD25 Recombinant Antibody (Basiliximab) | Human | Mouse IgG1 - kappa | FC, IP, ELISA, Neut, FuncS, IF, WB, etc. |
ZG-0100J | Mouse Anti-IL2RA Recombinant Antibody (clone Q22) | Human | Mouse IgG | IHC-P, IF (paraffin section) |
Creative Biolabs provides a diverse array of recombinant antibodies that are specifically designed to target IL2RA. These antibodies are meticulously crafted and subjected to rigorous testing to guarantee their superior quality. Our first-rate facilities and knowledgeable researchers are committed to precisely targeting IL2RA by means of each antibody. Our antibodies are a great tool for field-based researchers as they undergo extensive validation procedures and exhibit exceptional specificity, robust binding affinity, and great performance for a variety of study uses.
Fig.1 HPLC analysis of anti-CD25/IL2RA antibody
(Cat# TAB-023, Creative Biolabs).
Fig.2 SDS-PAGE analysis of anti-CD25/IL2RA antibody
(Cat# TAB-023, Creative Biolabs).
Fig.3 IHC analysis of anti-IL2RA antibody
(Cat# ZG-0100J, Creative Biolabs).
Fig.4 IHC analysis of anti-IL2RA antibody
(Cat# ZG-0100J, Creative Biolabs).
Creative Biolabs delivers a reliable assortment of high-quality anti-IL2RA antibodies, meticulously produced with state-of-the-art genetic engineering techniques.
Featured Anti-IL2RA Recombinant Antibody Production Platforms
Fig.5 Milligram-scale anti-IL2RA recombinant antibody production.
Fig.6 Gram-scale anti-IL2RA recombinant antibody production.
Creative Biolabs offers an extensive selection of premium anti-IL2RA recombinant antibodies available in multiple formats, designed to accommodate the diverse needs of researchers worldwide.
Fig.7 Full-length anti-IL2RA recombinant antibody production and modalities.
Table 2. Public drug targeting IL2RA.
Company | Research phase | Classification | Condition |
Cerimon Novartis (Originator) |
Launched - 1998 | Chimeric Monoclonal Antibodies |
Cytokine release syndrome Immunosuppression Inflammatory bowel disease Transplant rejection Transplant rejection, kidney Ulcerative colitis Uveitis |
Biogen (Originator) Roche (Originator) Shionogi |
Launched - 1992 |
Cancer Immunotherapy IL-2 Polypeptides, from 41 AA Recombinant proteins |
Angiosarcoma Cancer, colorectal, metastatic |
Abbott AbbVie Biogen Biogen Idec (Biogen) National Cancer Institute National Eye Institute (NEI) PDL BioPharma (Originator) Protein Design Labs (PDL BioPharma) Roche UCB |
Withdrawn - 2018 |
Cancer Immunotherapy Humanized Monoclonal Antibodies |
Asthma Diabetes type 1 Eye Disorders Hodgkin lymphoma Immunosuppression Leukemia-lymphoma, adult T-cell Multiple sclerosis Multiple sclerosis, relapsing-remitting Psoriasis Transplant rejection Transplant rejection, heart Transplant rejection, kidney Ulcerative colitis Uveitis |
Biotest (Originator) ElsaLys Biotech Jazz Pharmaceuticals OPi (Jazz Pharmaceuticals) |
Pre-Registered | Murine Monoclonal Antibodies | Graft-versus-host disease |
Mabpharm Mabtech (Sinomab) Sinomab (Originator) Sorrento Therapeutics TNK Therapeutics |
Phase III |
Chimeric Monoclonal Antibodies Follow-on Products |
Transplant rejection |
Second Xiangya Hosp Central South Univ (Originator) | Phase II |
IL-2 Polypeptides, from 41 AA Recombinant proteins |
Pemphigus vulgaris Urticaria |
Lilly Nektar Therapeutics (Originator) |
Phase II |
IL-2 Pegylated Drugs Polypeptides, from 41 AA Recombinant proteins |
Alopecia areata Atopic dermatitis Autoimmune disease Crohn's disease Graft-versus-host disease Plaque psoriasis Rheumatoid arthritis Systemic lupus erythematosus Ulcerative colitis |
Bioniz Therapeutics (Equillium) Equillium (Originator) |
Phase II |
Pegylated Drugs Peptides |
Alopecia areata Atopic dermatitis Cutaneous T-cell lymphoma HTLV-1-associated myelopathy-tropical spastic paraparesis Large granular lymphocytic leukemia Lymphocytic leukemia Vitiligo |
University of California Los Angeles (Originator) | Phase II | Transplant rejection | |
National Cancer Institute (Originator) | Phase II |
Fusion Proteins Immunotoxins Polypeptides, from 41 AA Toxins |
Chronic lymphocytic leukemia Cutaneous T-cell lymphoma Hairy cell leukemia Leukemia Lymphoma Melanoma |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
As a veteran leader in the antibody field, Creative Biolabs continues to introduce cutting-edge technologies and expertise to improve product characteristics and performance. If you are looking for reliable IL2RA antibody products, please feel free to contact us for inquiries.